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BACKGROUND AND PURPOSE: Recanalization is observed in 20–40% of endovascularly treated intra-
cranial aneurysms. To further reduce the recanalization and expand endovascular treatment, we
evaluated the safety and efficacy of closed-cell SACE.
MATERIALS AND METHODS: Between 2007 and 2010, 147 consecutive patients (110 women; mean
age, 54 years) presenting at 2 centers with 161 wide-neck ruptured and unruptured aneurysms were
treated by using SACE. Inclusion criteria were wide-neck aneurysms (4 mm or a dome/neck ratio
2). Clinical outcomes were assessed by the mRS score at baseline, discharge, and follow-up.
Aneurysm occlusion was assessed on angiograms by using the RS immediately after SACE and at
follow-up.
RESULTS: Eighteen aneurysms (11%) were treated following rupture. Procedure-related mortality and
permanent neurologic deficits occurred in 2 (1.4%) and 5 patients (3.4%), respectively. In total, 7
patients (4.8%) died, including 2 with reruptures. Of the 140 surviving patients, 113 (80.7%) patients
with 120 aneurysms were available for follow-up neurologic examination at a mean of 11.8 months. An
increase in mRS score from admission to follow-up by 1, 2, or 3 points was seen in 7 (6.9%), 1 (1%),
and 2 (2%) patients, respectively. Follow-up angiography was performed in 120 aneurysms at a mean
of 11.9 months. Recanalization occurred in 12 aneurysms (10%), requiring retreatment in 7 (5.8%).
Moderate in-stent stenosis was seen in 1 (0.8%), which remained asymptomatic.
CONCLUSIONS: This series adds to the evidence demonstrating the safety and effectiveness of SACE
in the treatment of intracranial aneurysms. However, SACE of ruptured aneurysms and premature
termination of antiplatelet treatment are associated with increased morbidity and mortality.
ABBREVIATIONS: ASA  acetylsalicylic acid; ISAT  International Subarachnoid Aneurysm Trial;
mRS  modified Rankin Scale; RS  Raymond score; SACE  stent-assisted coil embolization
Despite ongoing concerns about the durability of endovas-cular treatment of intracranial aneurysms, coiling has
been increasingly accepted worldwide. The multicenter ran-
domized ISAT,1-3 showing long-term improved safety and
clinical outcome in patients treated with coil embolization
compared with open clipping, has accelerated this trend,4 in-
creasing the number of patients being referred for endovascu-
lar treatment and thus further emphasizing the need to en-
hance the ability to treat intracranial aneurysms effectively.
However, large, giant, and wide-neck aneurysms can be diffi-
cult to treat because of the significant risk of coil herniation
from the aneurysm into the parent artery.5-7 While the goal of
endovascular treatment is complete exclusion of the aneurysm
from the circulation while preserving the parent and side-
branch artery lumen, this is often not possible. Even with ad-
junctive techniques such as balloon remodeling, large, giant,
and wide-neck aneurysms remain challenging, with a signifi-
cant number of subtotal occlusions. In addition, aneurysm
recanalization is observed in 20%–40% of cases due to coil
compaction, migration of coils into the aneurysm thrombus,
or aneurysm growth.7-10
Introduction of stents designed as an adjunct tool for coil-
ing has been shown, in the short-term, to be of beneficial val-
ue.11-15 However, a variety of devices, different in their design
and coating, was used with a high periprocedural mortality
and morbidity.15,16 This study was designed to evaluate 1 spe-
cific stent available for aneurysm treatment, regarding the
periprocedural and safety profile as well as efficacy. Our hy-
pothesis was that stent-assisted coil embolization reduces re-
canalization and retreatment rates compared with historical
controls17 without impacting procedural safety in a subgroup
of wide-neck aneurysms or in those with a dome/neck ratio of
2.
Materials and Methods
Patients and Techniques
From June 2007 to June 2010, consecutive patients harboring intra-
cranial aneurysms treated with Enterprise (Codman Neurovascular,
Raynham, Massachusetts) SACE were enrolled in a prospective data
base at 2 participating centers. All procedures were approved by the
local institutional review board at each participating site. Inclusion
criteria were the following: 1) wide-neck aneurysm: defined as one
having a neck dimension that is4 mm or a dome/neck ratio that is
2; 2) parent vessel diameter of 4 mm; 3) any use of a closed-cell
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stent for coil embolization; and 4) patient or health care proxy in-
formed consent. Patients younger than 18 years and pregnant women
were excluded. Patients treated with open-cell stents were excluded.
At the participating centers, all ruptured aneurysms are treated, and
treatment of unruptured aneurysms is performed after careful assess-
ment of perceived risk factors for rupture18,19 and consultation with
our multidisciplinary cerebrovascular team and patients.
Angiographic and Endovascular Procedures
All endovascular procedures were performed by senior neurointer-
ventionalists by using a biplane angiography unit with 3D rotational
angiography capability (Allura Xper FD20/20; Philips Healthcare,
Best, the Netherlands) with patients under general anesthesia. Pa-
tients were given ASA (80 mg) and clopidogrel (75 mg) for a mini-
mum of 3 days before the procedure. Dual antiplatelet treatment was
continued for a minimum of 6 months, followed by life-long contin-
uation of ASA. In cases of acute aneurysm rupture, patients were
administered 350 mg of ASA and 150 mg of clopidogrel through a
nasogastric tube at a minimum of 1 hour before commencing the
procedure. Most important, in ruptured cases, the neurosurgery and
neurointensive care teams were consulted to assess the need for ven-
triculostomy before administering antiplatelet medication. Endovas-
cular access was obtained by a standard transfemoral approach. Fol-
lowing access, patients were heparinized to maintain activated
clotting time 250 seconds (for ruptured and unruptured aneu-
rysms). The stent delivery microcatheter was first positioned across
the neck of the aneurysm followed by placement of the coilingmicro-
catheter within the aneurysm. All aneurysmswere embolized by using
the semi-jailing20 or jailing technique. Aneurysms were coiled as
densely as possible with coils selected per the operator’s preference.
Any technical complication, with or without clinical sequelae, was
recorded.
Aneurysm occlusion was estimated by independent reviewers not
involved in patient care, by using a 3-point RS21 (RS 1, complete
obliteration of aneurysm and neck; RS 2, neck remnant without con-
trast filling the aneurysm sac; and RS 3, contrast filling the aneurysm
sac) immediately after SACE and at follow-up. After the procedure,
patients were transferred to the neurosurgical intensive care unit.
Packing attenuation, the volume ratio of implanted coils to the vol-
ume of the aneurysm, was calculated as previously described.9 We
calculated coil volume for each aneurysm, assuming that the coil was
a solid cylinder by using the primary coil diameter given in the man-
ufacturer’s specifications.
Clinical Evaluation
A complete neurologic examination was performed in all patients at
baseline, immediately after the procedure, at discharge, and at fol-
low-up by experienced physicians certified in stroke assessment. An
mRS score was assessed at baseline for unruptured cases, at discharge,
and at follow-up evaluations. For ruptured aneurysms, the Hunt and
Hess grade was recorded at baseline. Primary adverse events included
death and stroke. Secondary adverse events recorded were transient
ischemic attack, the need for re-intervention, and the presence of
hematomas. Residual aneurysm size was determined by angiography.
Medical histories, procedural reports, and clinical outcomes were re-
corded in this prospective data base.
Statistical Analysis
All data are presented as the mean the standard error of the mean.
Comparisons of categoric data were performed by using the Fisher
exact test inGraphPad InStat (http://www.softpedia.com/get/Others/
Finances-Business/GraphPad-InStat.shtml). Significant differences
were established for P .05.
Results
Patient Information and Technical Results
We enrolled 147 patients harboring 161 aneurysms that were
embolized via SACE. Eighteen aneurysms (11%) were treated
acutely following rupture. Patient demographic information
and aneurysm characteristics/location are provided in Table 1.
Most aneurysms were discovered incidentally (55%) and were
of wide-neck saccular morphology (60%). The mean aneu-
rysm and neck diameters were 6.5  0.4 and 5.1  0.3 mm,
respectively; the dome/neck ratio was 1.3 0.04. In 2 cases of
a small aneurysm and a dissecting aneurysm, no coils were
used in conjunctionwith the stent. In another 2 cases, the stent
was resheathed following successful coil embolization by us-
ing the semi-jailing technique.20 In total, 167 stents were used
(1.03 stents/aneurysm, 6 patients received 2 stents). The pack-
ing attenuation obtained was 43 3%. Of all stented vessels,
19 measured2 mm (mean, 1.7 0.04 mm).
During the procedure, clot formation on the surface of the
Table 1: Patient demographics and aneurysm information
No.
Patients 147
Aneurysms 161
Females 110 (74.8%)
Mean age (yr) 54.0
Age range (yr) 27–81
Presentation/indications for treatment
SAH 18 (11%)
Headache/incidental 80 (55%)
Recurrence after coiling 27 (18%)
Stroke/transient ischemic attack 13 (9%)
Mass effect 7 (5%)
Recurrence after clipping/failed clipping 2 (1%)
Aneurysm dimensions
Mean aneurysm dome size (SEM) 6.5 (0.4) mm
Mean aneurysm neck size (SEM) 5.1 (0.3) mm
Dome/neck ratio (SEM) 1.3 (0.04)
Aneurysm Location
ACA 4 (2.5%)
AcomA 15 (9.5%)
BA 15 (9.5%)
Cavernous ICA 14 (9%)
Paraclinoid ICA 18 (11%)
Extracranial ICA 3 (2%)
ICA terminus 6 (4%)
MCA 18 (11%)
Ophthalmic/paraophthalmic 23 (14%)
PcomA 23 (14%)
PICA 2 (1%)
SCA 2 (1%)
Superior hypophyseal 12 (7.5%)
VA 6 (4%)
Morphology
Wide-neck saccular 95 (60%)
Fusiform/dissecting 24 (15%)
Blister 8 (5%)
Recurrence (clipping or coiling) 34 (20%)
Note:—SEM indicates standard error of the mean; ACA, anterior cerebral artery; AcomA,
anterior communicating artery; BA, basilar tip; PcomA, posterior communicating artery;
SCA, superior cerebellar artery; VA vertebral artery.
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stent was observed in 11 (6.8%) cases, all of which were suc-
cessfully treated with intra-arterial administration of abcix-
imab (5–18 mg).22 During coiling, inadvertent aneurysm per-
foration was encountered in 3 aneurysms (1.9%) without
clinical sequelae. Angiography revealed vasospasm due to
catheter manipulation in 20 (12.4%) cases, which promptly
resolvedwith local intra-arterial administration of nicardipine
(2–15 mg).23 A single (0.6%) instance of proximal stent mi-
gration occurred following SACE of a basilar tip aneurysm, in
which a 14-mm stent was deployed from the right P1 segment
of the posterior cerebral artery to the basilar artery without
untoward events. In 6 (3.7%) cases, coil material herniated
into the parent vessel that was subsequently pinned between
the stent and artery following full stent deployment.
Clinical Outcome
Seven patients (4.8%) died, including 2 with reruptures (Ta-
bles 2 and 3). There were 5 (3.4%) and 3 (2%) minor and
major strokes, respectively, within 30 days of the procedure.
During this period, 6 patients (4.1%) experienced a transient
ischemic attack. The 30-day combined cardiac and pulmonary
complication rate was 2.5%. Five patients (3.4%) had access-
site complications, including groin hematoma (4 patients)
and suture-induced femoral artery constriction requiring sur-
gical repair (1 patient). One patient developed hydrocepha-
lous 30 days after SACE of a ruptured aneurysm.
Of the 140 surviving patients, 113 (80.7%) with 120 aneu-
rysms were available for follow-up neurologic examination at
a mean of 11.8 months (95% CI, 10.5–13.2 months). Of pa-
tients in the unruptured aneurysm cohort available for fol-
low-up (n 101), an increase in the mRS score from admis-
sion to follow-up by 1, 2, or 3 points was seen in 7 (6.9%), 1
(1%), and 2 (2%) patients, respectively (Fig 1). After adjudi-
cation of complications by the senior neurointerventionalists,
procedure-related mortality and permanent neurologic defi-
cits occurred in 2 (1.4%) and 5 patients (3.4%), respectively
(Tables 2 and 3).
Angiographic Results
Follow-up angiography was performed in 120 aneurysms at a
mean of 11.9 months (95% CI, 10.6–13.2 months) (illustra-
tive case, Fig 2). Of the angiographic follow-ups, the number
of aneurysms at each time point was the following: 3 at 6
months, 48 from6 to 11months, 62 from12 to 24months, and
7 at 24 months. Aneurysms were more likely to be com-
pletely occluded at follow-up, suggesting progressive throm-
bosis (P  .0001) (Fig 3). Recanalization, defined as any in-
crease in the RS from the postprocedural angiogram, was seen
in 12 aneurysms (10%). Of the recanalized aneurysms, 7
(5.8%) were subsequently retreated. No adverse events were
seen as a result of the retreatment. Intimal hyperplasia produc-
ing a mild (20%) or moderate (20%; 70%) narrowing
was seen in 6 (5%) and 1 (0.8%) of the stented segments,
respectively. All patients with angiographic evidence of vessel
narrowing remained asymptomatic. Of the stented segments
in vessels that measured 2 mm, there were 2 (10.5%) mild
and 1 (5.3%) moderate case of in-stent stenosis.
Discussion
Technologies such as balloon remodeling24,25 and stent-assisted
coiling11-13,26,27 have enabled endovascular treatment of wide-
neck complex aneurysms. A large multicenter prospective trial
recently compared the safety profile of the balloon remodeling
techniquewith that of coil embolization alone in unruptured an-
eurysms.28 Themorbidity andmortality in the balloon remodel-
ing group were 2.3% and 1.4%, respectively, and rates did not
differ from those in the standard treatment group. A recent ret-
rospective study of SACE in both ruptured and unruptured an-
eurysms reported procedure-related morbidity and mortality
rates of 7.4% and 4.6%, respectively.15 This latter study included
Table 2: Neurologic complications and mortality (unruptured
aneurysms)
Change in
mRSa
Frequency (No.
of Patients) Description (No.)
1 7 New or more severe headache (4), mild
extremity weakness (3), visual field
deficit (1)
2 1 Stroke after termination of antiplatelet
therapy 60 days posttreatment
3 2 Anterior choroidal artery stroke (1);
stroke after termination of
antiplatelet therapy 10 months post-
treatment (1)
6b 2 Sneddon syndrome, withdrawal of
medical care after thromboembolism
(1); stroke 6 months after treatment
(1)
a Increase in mRS from baseline (mRSfollow-up  mRSbaseline).
b All patients with unruptured aneurysms who died, absolute mRS score.
Table 3: Neurologic outcomes and mortality (ruptured aneurysms)
mRS
Frequency (No.
of Patients)a Description (No.)
0 8
2 3 Residual deficit after SAH (2), stroke due to
stent occlusion after stopping antiplatelet
therapy for shunt placement 2 months after
procedure (1)
3 1 Symptomatic intracranial hemorrhage following
shunt revision while on antiplatelet therapy
(1)
6 5 Aneurysm rebleeding (2), complications of SAH/
vasospasm (3)
a One patient lost to follow-up.
Fig 1. mRS score as a percentage of patients scored at baseline (141 patients, excludes
those presenting with aneurysmal subarachnoid hemorrhage), discharge (159 patients), and
follow-up (113 patients). Two patients having 2 aneurysms each were treated in a single
session.
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all commercially available stent technologies, and the authors re-
ported that procedure-related complications were dependent on
the stent used. To remove this variable, amulticenter registrywas
performed to evaluate the acute clinical outcomes by using the
Enterprise stent, and it found permanentmorbidity andmortal-
ity rates of 2.8% and 2%, respectively.14
We report the midterm clinical outcome for aneurysms
treated by closed-cell SACE. In unruptured aneurysms, overall
morbidity, defined as any increase in mRS at follow-up, and
mortality were 10.3% and 1.6%, respectively. Permanent ma-
jor morbidity (mRS score of 2 at follow-up) in the unrup-
tured aneurysm cohort was seen in 4 patients (3.1%). If one
uses similar criteria for comparison of SACE in this series with
balloon-remodeling previously reported,28mortality is similar
and morbidity is slightly higher. Although it is convenient to
compare these data with the balloon-remodeling experience,
our centers frequently use the balloon-remodeling technique,
and SACE is reserved for aneurysms with an exceedingly poor
dome/neck ratio that approaches 1. Additionally, in this series,
poor outcomes were mostly related to thromboembolic com-
plications associated with premature termination of systemic
dual-antiplatelet therapy rather than the SACE procedure.
Fig 2. A 59-year-old man referred for embolization of an incidentally discovered MCA aneurysm. 3D rotational angiography (A, frontal view) and DSA (B ) show a wide-neck aneurysm
involving both the smaller superior and the larger inferior M2 divisions (arrowheads) as well as the anterior temporal artery (double arrows). Note an aneurysm bleb projecting superiorly
(arrow). Partial stent deployment (semi-jailing technique20) with placement of a framing coil (C ). Compartmental coiling with smaller fill coils and deployment of the stent (D ). Final early
and late arterial phase angiogram (E and F ) shows obliteration of the aneurysm with delayed filling of the bleb (arrow, Raymond Class 3) and preservation of all involved MCA branches.
Twenty-four-hour follow-up angiogram before discharge after discontinuation of the intraprocedural therapeutic heparin shows lack of delayed contrast filling of the bleb, most likely
representing further thrombosis (G ). Twelve-month follow-up angiogram (H ) shows stable and complete aneurysm occlusion with preservation of all MCA branches.
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We enrolled 18 patients in the acute period following sub-
arachnoid hemorrhage, and themorbidity andmortality rates
were 22% and 28%, respectively. These outcomes are similar
to those reported for SACE in ruptured aneurysms.16 How-
ever, this complication rate does not compare favorably with
that in the ISAT, inwhich 23.7%of patientswere dependent or
dead 1 year following endovascular coiling.1 One explanation
for the lower rate of good outcomes in our study might be the
inclusion of dissecting aneurysms (n  6, 33%), which were
excluded in the ISAT trial. Two significant complications oc-
curred in our study when patients developed hydrocephalous
1–2months following SACE of ruptured aneurysms. In 1 case,
antiplatelet therapy was halted for shunt placement with sub-
sequent in-stent thrombosis. In another case, shunt revision
was performed with the patient on antiplatelet therapy, lead-
ing to symptomatic intracranial hemorrhage. Additionally, 2
deaths were associated with aneurysm rebleeding after SACE.
One case of rebleeding was from a dissecting aneurysm, where
the rebleed occurred 4 days after embolization. These data
demonstrate the increased risk of using stents for aneurysm
embolization versus coiling alone or balloon-remodeling in
ruptured aneurysms.
Recently, a large meta-analysis reported aneurysm recur-
rence and retreatment following coil embolization in 20.8%
and 10.3% of cases, respectively.17 Angiographic results re-
ported herein demonstrate a high rate of progressive throm-
bosis of the aneurysm and complete aneurysm obliteration on
follow-up. Aneurysm recurrence (10%) and retreatment
(5.8%) were considerably lower with SACE despite the wide-
neck morphology, which is associated with worse angio-
graphic outcomes.10 Intimal hyperplasia induced by the pres-
ence of the stent within the parent artery leads to remodeling,
thereby permanently excluding the aneurysm.
Limitations of this study are the lack of a direct control
group and the relatively small number of ruptured aneurysms
included in the study. Follow-up at amean of 11.8months was
available in only 80% of patients. Patients were lost to fol-
low-up either due to refusal to return for clinical examination
or angiography or change of contact information with no for-
warding instructions. Because our study enrolled prospec-
tively all consecutive patients receiving SACE with a closed-
cell device, our study included heterogeneous aneurysm
morphologies including blister and dissecting aneurysms as
well as both ruptured and unruptured aneurysms. We further
included 2 cases in which the device was resheathed and not
implanted, as well as 2 cases in which coiling was not possible.
Conclusions
SACE of wide-neck unruptured aneurysms with a closed-cell
device is safe and produces durable and high occlusion rates;
however, increased morbidity and mortality observed in rup-
tured aneurysms are associated with dual-antiplatelet treat-
ment required for stent placement.
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